[5] Atogepant was approved for medical use in the United States in September 2021,[4][8] and in the European Union in August 2023.

[10] The benefits and side effects of atogepant were evaluated in two clinical trials of 1,562 participants with a history of migraine headaches occurring on 4 to 14 days per month.

[11] The UK’s National Institute for Health and Care Excellence has issued draft guidance recommending atogepant for preventing episodic and chronic migraine in NHS patients.

It's approved for those experiencing at least 4 migraine days per month after failing 3 prior treatments.

[12] Atogepant demonstrated efficacy in two phase 3 trials (ADVANCE and PROGRESS) by significantly reducing monthly migraine days, acute medication use, and improving quality of life in patients with episodic and chronic migraine over 12 weeks compared to placebo.